Literature DB >> 25663248

Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature.

Ana-Maria Vranceanu1, Vanessa L Merker, Elyse R Park, Scott R Plotkin.   

Abstract

The aim of this research is to identify, within a systematic review, aspects of quality of life (QoL) that are adversely affected in children and adolescents with neurofibromatosis (NF), and to report predictors of quality of life in this population. Published reports of original research were included if they described QoL in children and/or adolescents with NF, and met methodological quality according to a list of predefined criteria. Seven studies conducted between 2006 and 2013 met inclusion criteria. All seven studies examined patients with NF1 and reported that these patients have lower general QoL compared to population norms. Parents' proxy ratings of QoL were generally lower than children's self-report ratings. By parent proxy, familial NF1 was a strong protective factor for QoL, while the opposite was found by child report. By parent proxy, male sex was significantly associated with lower scores on the parental time impact of QoL. Skin-related QoL was only slightly altered in this population, vision-specific QoL was impacted only in patients with vision loss. The majority of findings regarding predictors of QoL in children with NF1 were weak, due to a lack of studies, heterogeneity of samples, and heterogeneity of measurements/predictors assessed. Future studies should examine more comprehensively the psychosocial factors affecting the NF population, especially in young patients with NF2 and schwannomatosis, who have been neglected in prior research. The use of consistent QoL measures is preferred to allow better comparison among studies and conditions. Interventions, including comprehensive mind-body treatments, are warranted to address impaired QoL in children and adolescents with NF1.

Entities:  

Mesh:

Year:  2015        PMID: 25663248     DOI: 10.1007/s11060-015-1725-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

Review 1.  Physical risk factors for neck pain.

Authors:  G A Ariëns; W van Mechelen; P M Bongers; L M Bouter; G van der Wal
Journal:  Scand J Work Environ Health       Date:  2000-02       Impact factor: 5.024

Review 2.  Children's experiences of cystic fibrosis: a systematic review of qualitative studies.

Authors:  Nathan Jamieson; Dominic Fitzgerald; Davinder Singh-Grewal; Camilla S Hanson; Jonathan C Craig; Allison Tong
Journal:  Pediatrics       Date:  2014-06       Impact factor: 7.124

3.  The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.

Authors:  Ana-Maria Vranceanu; Vanessa L Merker; Scott R Plotkin; Elyse R Park
Journal:  J Neurooncol       Date:  2014-07-15       Impact factor: 4.130

4.  Parent-reported health outcomes in infants/toddlers: measurement properties and clinical validity of the ITQOL-SF47.

Authors:  Jeanne M Landgraf; Ineke Vogel; Rianne Oostenbrink; Margriet E van Baar; Hein Raat
Journal:  Qual Life Res       Date:  2012-04-17       Impact factor: 4.147

Review 5.  Prognostic factors of whiplash-associated disorders: a systematic review of prospective cohort studies.

Authors:  Gwendolijne G M Scholten-Peeters; Arianne P Verhagen; Geertruida E Bekkering; Daniëlle A W M van der Windt; Les Barnsley; Rob A B Oostendorp; Erik J M Hendriks
Journal:  Pain       Date:  2003-07       Impact factor: 6.961

6.  Parental reports of health-related quality of life in young children with neurofibromatosis type 1: influence of condition specific determinants.

Authors:  Rianne Oostenbrink; Kimberly Spong; Arja de Goede-Bolder; Jeanne M Landgraf; Hein Raat; Henriette A Moll
Journal:  J Pediatr       Date:  2007-08       Impact factor: 4.406

7.  Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases.

Authors:  P Wolkenstein; D Rodriguez; S Ferkal; H Gravier; V Buret; N Algans; M-C Simeoni; S Bastuji-Garin
Journal:  Br J Dermatol       Date:  2008-12-05       Impact factor: 9.302

Review 8.  Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.

Authors:  Pamela L Wolters; Staci Martin; Vanessa L Merker; Kathy L Gardner; Cynthia M Hingtgen; James H Tonsgard; Elizabeth K Schorry; Andrea Baldwin
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

9.  The European DISABKIDS project: development of seven condition-specific modules to measure health related quality of life in children and adolescents.

Authors:  Rolanda M Baars; Clare I Atherton; Hendrik M Koopman; Monika Bullinger; Mick Power
Journal:  Health Qual Life Outcomes       Date:  2005-11-13       Impact factor: 3.186

Review 10.  The Neurofibromatoses. Part 1: NF1.

Authors:  Christine Lu-Emerson; Scott R Plotkin
Journal:  Rev Neurol Dis       Date:  2009
View more
  15 in total

1.  Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program.

Authors:  Ethan G Lester; Eric A Macklin; Scott Plotkin; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2020-02-20       Impact factor: 4.130

2.  PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity.

Authors:  Kavitha Nutakki; James W Varni; Nancy L Swigonski
Journal:  J Neurooncol       Date:  2017-12-22       Impact factor: 4.130

3.  Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with Neurofibromatosis Type 1.

Authors:  James W Varni; Kavitha Nutakki; Nancy L Swigonski
Journal:  Qual Life Res       Date:  2018-11-21       Impact factor: 4.147

4.  Development of the pediatric quality of life inventory neurofibromatosis type 1 module items for children, adolescents and young adults: qualitative methods.

Authors:  Kavitha Nutakki; James W Varni; Sheila Steinbrenner; Claire B Draucker; Nancy L Swigonski
Journal:  J Neurooncol       Date:  2017-01-11       Impact factor: 4.130

5.  Benign Hand Tumors (Part II): Soft Tissue Tumors.

Authors:  Jonathan Lans; Kai-Lou C Yue; René M Castelein; David I Suster; G Petur Nielsen; Neal C Chen; Santiago A Lozano-Calderon
Journal:  Hand (N Y)       Date:  2020-07-15

6.  Quality of Life in Adults with Neurofibromatosis 1 in Brazil.

Authors:  Natália Parenti Bicudo; Balduíno Ferreira de Menezes Neto; Lucimar Retto da Silva de Avó; Carla Maria Ramos Germano; Débora Gusmão Melo
Journal:  J Genet Couns       Date:  2016-03-05       Impact factor: 2.537

7.  Worries and needs of adults and parents of adults with neurofibromatosis type 1.

Authors:  Andre B Rietman; Hanneke van Helden; Pauline H Both; Walter Taal; Jeroen S Legerstee; AnneLoes van Staa; Henriette A Moll; Rianne Oostenbrink; Agnies M van Eeghen
Journal:  Am J Med Genet A       Date:  2018-05       Impact factor: 2.802

8.  Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis.

Authors:  Shivani Ahlawat; Asad Baig; Jaishri O Blakeley; Michael A Jacobs; Laura M Fayad
Journal:  J Magn Reson Imaging       Date:  2016-03-17       Impact factor: 5.119

9.  Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.

Authors:  Pamela L Wolters; Ana-Maria Vranceanu; Heather L Thompson; Staci Martin; Vanessa L Merker; Andrea Baldwin; Carolina Barnett; Kimberley S Koetsier; Cynthia M Hingtgen; Christopher J Funes; James H Tonsgard; Elizabeth K Schorry; Taryn Allen; Taylor Smith; Barbara Franklin; Stephanie Reeve
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

10.  Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.

Authors:  Sheilagh Maguiness; Yemima Berman; Nathan Rubin; Melissa Dodds; Scott R Plotkin; Claire Wong; Christopher Moertel
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.